Subtype
HHV8-Related Malignant Neoplasm
CI-CAN-00002871Explore in graph →
26 active trials4 approved drugs
- NCIt
- C27697
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002871Explore in graph →
Clinical trials
146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01961063 | Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02659930 | Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04941274 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04303117 | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT02337985 | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03157167 | An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) | completed | Phase 1 | 15 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | terminated | Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT01495598 | Pomalidomide for Kaposi Sarcoma in People With or Without HIV | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00000987 | A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00001113 | A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00000660 | Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000681 | A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000725 | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 56 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000763 | A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 42 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000694 | A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 18 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000695 | Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000954 | A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 72 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 29, 2021 | clinicaltrials |
| NCT00000769 | A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00287495 | BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01752569 | A Study of Selumetinib in Patients With Kaposi's Sarcoma(SCART) | terminated | Phase 1 / Phase 2 | 19 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 31, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00686842 | PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma | terminated | Phase 1 / Phase 2 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01016730 | Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2018 | clinicaltrials |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00001535 | Twins Study of Gene Therapy for HIV Infection | completed | Phase 1 | 48 | National Human Genome Research Institute (NHGRI)NIH | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00002136 | A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002137 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002138 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002153 | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders | completed | Phase 1 | 25 | DEKK-TEC, Inc.INDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002262 | A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma | completed | Phase 1 | — | University of California, San FranciscoOTHER | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002342 | A Study of Tecogalan Sodium | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials